Oxygen Therapy in Schizophrenia
|ClinicalTrials.gov Identifier: NCT00525863|
Recruitment Status : Unknown
Verified May 2008 by Beersheva Mental Health Center.
Recruitment status was: Recruiting
First Posted : September 6, 2007
Last Update Posted : May 28, 2008
Due to intense ATP-consuming processes in the brain, a high level of brain energy supply is required. A popular hypothesis regarding the pathogenesis and pathophysiology of schizophrenia postulates hypofunction of neuronal circuits in the prefrontal and limbic-temporal areas. An emerging body of data suggests that impaired energy metabolism due to mitochondrial dysfunction plays a role in the pathophysiology of schizophrenia.
Under normal conditions cellular metabolic rate, i.e. oxygen and glucose consumption, increases proportionally with any increase in neuronal activity. The impaired energy metabolism due to mitochondrial dysfunction and frontal lobe hypofunction might be improved by increasing O2 supply to the brain. Oxygen-enriched air inhalation has been shown to increase brain oxygen supply. Hyperoxia therapy is a useful tool in the treatment of neurological and neurotrauma deficits.
We therefore suggest a randomized double blind cross-over study of enriched inspired O2 partial pressure in schizophrenia.
It is surprising given the numerous findings on reduced energy metabolism in schizophrenia that simple treatment with inspired enriched oxygen has not been studied.
|Condition or disease||Intervention/treatment||Phase|
|Chronic Schizophrenia||Drug: oxygen||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Oxygen Therapy in Schizophrenia|
|Study Start Date :||January 2008|
|Estimated Primary Completion Date :||December 2009|
|Estimated Study Completion Date :||December 2009|
- PANSS [ Time Frame: every two weeks ]
- Clinical Global Impressions [ Time Frame: every two weeks ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00525863
|Contact: Yuly Bersudsky, MD, PhDemail@example.com|
|Beersheva Mental Health Center||Recruiting|
|Contact: Yuly Bersudsky, MD, PhD 9728-6401602 firstname.lastname@example.org|
|Principal Investigator:||Yuly Bersudsky, MD, PhD||Ben-Gurion University of the Negev|